Clinical Trial Detail

NCT ID NCT01999985
Title Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung cancer

lung non-small cell carcinoma

Therapies

Afatinib + Dasatinib

Age Groups: adult senior

No variant requirements are available.